ANI Pharmaceuticals (ANIP) announced that following final approval from the U.S. FDA for its Abbreviated New Drug Application, the company launched Estradiol Gel, 0.06%. ANI’s Estradiol Gel, 0.06% is the generic version of the reference listed drug EstroGel Gel, 0.06%. U.S. annual sales for Estradiol Gel, 0.06% total approximately $16.7M, based on August 2024 moving annual total (MAT) IQVIA data.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals price target raised to $62 from $60 at Truist
- ANI Pharmaceuticals initiated with an Overweight at Piper Sandler
- ANI Pharmaceuticals announces FDA approval, launch of Ketoconazole Shampoo, 2%
- ANI Pharmaceuticals price target raised to $83 from $81 at Raymond James
- ANI Pharmaceuticals completes acquisition of Alimera Sciences